Selenium-binding protein 1 (SBP1) has been shown to be greatly reduced in various human cancers. The purpose of this study was to evaluate the expression of SBP1 in precursor lesions and gastric carcinoma (GC) and to discuss the specific role of SBP1 in gastric carcinogenesis. Using tissue microarray (TMA) technology and immunohistochemical (IHC) survey, SBP1 expressions were evaluated based on a semi-quantitative scoring system developed for this study in 25 paired of GC and corresponding nonneoplastic epithelia tissues, 21 gastric ulcer, 13 gastric polyp, 19 chronic atrophic gastritis, 20 intestinal metaplasia, and 16 dysplasia tissues. We found abundant expression of SBP1 in most precursor lesions in addition to the nonneoplastic epithelia tissues. However, the expression of SBP1 was severely suppressed in most of the GC tissues (P = 0.000). Although no statistical differences were found between the expressions of SBP1 in gastric tissues with different levels of intestinal metaplasia or dysplasia (P > 0.05), the reduction in SBP1 seems to be correlated with clinical stage of GC (P = 0.044). Thus, SBP1 can be supposed as a diagnosis marker of GC. The suppression of SBP1 may be a late event in gastric carcinogenesis.
Selenium-binding protein 1 Gastric carcinoma Precursor lesion Tissue microarray Immunohistochemistry
This is a preview of subscription content, log in to check access.
The authors declare that they have no competing interests.
Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.PubMedCrossRefGoogle Scholar
Alaejos MS, Diaz Romero FJ, Diaz Romero C. Selenium and cancer: some nutritional aspects. Nutrition. 2000;16:376–83.PubMedCrossRefGoogle Scholar
Rudolph RE, Vaughan TL, Kristal AR, Blount PL, Levine DS, et al. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett’s esophagus. J Natl Cancer Inst. 2003;95:750–7.PubMedCrossRefGoogle Scholar
Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, et al. Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial. Cancer Epidemiol Biomarkers Prev. 2002;11:1285–91.PubMedGoogle Scholar
Combs GF Jr. Current evidence and research needs to support a health claim for selenium and cancer prevention. J Nutr. 2005;135:343–7.PubMedGoogle Scholar
Brinkman M, Buntinx F, Muls E, Zeegers MP. Use of selenium in chemoprevention of bladder cancer. Lancet Oncol. 2006;7:766–74.PubMedCrossRefGoogle Scholar
Meuillet E, Stratton S, Prasad Cherukuri D, Goulet AC, Kagey J, et al. Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings. J Cell Biochem. 2004;91:443–58.PubMedCrossRefGoogle Scholar
Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal. 2007;9:775–806.PubMedCrossRefGoogle Scholar
Bansal MP, Mukhopadhyay T, Scott J, Cook RG, Mukhopadhyay R, et al. DNA sequencing of a mouse liver protein that binds selenium: implications for selenium’s mechanism of action in cancer prevention. Carcinogenesis. 1990;11:2071–3.PubMedCrossRefGoogle Scholar
Jeong JY, Wang Y, Sytkowski AJ. Human selenium binding protein-1 (hsp56) interacts with vdu1 in a selenium-dependent manner. Biochem Biophys Res Commun. 2009;379:583–8.PubMedCrossRefGoogle Scholar
Yang M, Sytkowski AJ. Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res. 1998;58:3150–3.PubMedGoogle Scholar
Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, et al. Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol. 2004;202:321–9.PubMedCrossRefGoogle Scholar
Huang KC, Park DC, Ng SK, Lee JY, Ni X, et al. Selenium binding protein 1 in ovarian cancer. Int J Cancer. 2006;118:2433–40.PubMedCrossRefGoogle Scholar
Kim H, Kang HJ, You KT, Kim SH, Lee KY, et al. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics. 2006;6:3466–76.PubMedCrossRefGoogle Scholar
Li T, Yang W, Li M, Byun DS, Tong C, et al. Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res. 2008;52:1289–99.PubMedCrossRefGoogle Scholar
Pohl NM, Tong C, Fang W, Bi X, Li T, Yang W. Transcriptional regulation and biological functions of selenium-binding protein 1 in colorectal cancer in vitro and in nude mouse xenografts. PLoS One. 2009;4(11):e7774.PubMedCrossRefGoogle Scholar
He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, et al. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics. 2004;4:3276–87.PubMedCrossRefGoogle Scholar
Zeng X, Liao AJ, Tang HL, Yi L, Xie N, et al. Screening human gastric carcinoma-associated antigens by serologic proteome analysis. Ai Zheng. 2007;26:1080–4.PubMedGoogle Scholar
Wu C, Luo Z, Chen X, Wu C, Yao D, et al. Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers. Oncol Rep. 2009;21:1429–37.PubMedCrossRefGoogle Scholar
Jin Zhang, Jun Lin, Wei-guo Dong. Reduced selenium-binding protein 1 is associated with poor survival rate in gastric carcinoma. Med Oncol. doi:10.1007/s12032-010-9482-7.
Sobin LH, Wittekind CH. International union against cancer (UICC): TNM classification of malignant tumours. 5th ed. New York: Wiley; 1997. p. 54–8.Google Scholar
Porat A, Sagiv Y, Elazar Z. A 56-kDa selenium-binding protein participates in intra-golgi protein transport. J Biol Chem. 2000;275:14457–65.PubMedCrossRefGoogle Scholar
Antonioli DA. Precursors of gastric carcinoma: a critical review with a brief description of early (curable) gastric cancer. Hum Pathol. 1994;25:994–1005.PubMedCrossRefGoogle Scholar
Ho SB. Premalignant lesions of the stomach. Semin Gastrointest Dis. 1996;7:61–73.PubMedGoogle Scholar
Ming SC. Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer. 1998;1:31–50.PubMedCrossRefGoogle Scholar
Kapadia CR. Gastric atrophy, metaplasia, and dysplasia: a clinical perspective. J Clin Gastroenterol. 2003;36:S29–36. discussion S61–S62.PubMedCrossRefGoogle Scholar